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Abstract 
Cancer is one of the most important reasons of mortality in the world. However, there are several therapeutic plat-
forms to treat patients who suffering from cancer common treatments such as surgery, chemotherapy and etc. 
The current therapeutic approaches are related to some limitations. Hence, more understanding about molecular 
mechanisms that involved in cancer particularly in breast cancer pathogenesis, could contribute to provide better 
therapeutic platforms. Recently, non-coding RNAs such as microRNAs have attracted researchers’ attention in the field 
of cancer due to their functions in gene expression’s regulation and functional interactions with other molecules. 
Interestingly, great advances in next-generation sequencing lead to considering other roles for another non-coding 
RNAs subgroup called PIWI-interacting RNAs (piRNAs) in addition to their functions in the germline. Novel studies 
investigated the role of piRNAs in several cancers including lung cancer, hepatocellular carcinoma, gastric cancer, 
multiple myeloma and colorectal cancer. Hopefully, based on new findings, piRNAs may be a potential biomarker 
which can be used as a tool to diagnose or treat breast cancer. Thus, this review aimed to discuss the role of piRNAs in 
breast cancer progression and metastasis as well as its molecular mechanisms.
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Background
Breast disorders are very important disorders among 
women [1]. Among them, Breast cancer is the most 
common malignancy among women and it is the prin-
ciple cause of women’s death all over the world. In spite 
of great progress in the field of cancer, breast cancer is 
still a serious health problem among women which has 
complicated properties heterogeneously and shows a 
number of biological and clinical manifestations [2–4]. 
Breast cancer has been categorized into five groups based 
on expression patterns of three receptors: the estrogen 
receptor, progesterone receptor and human epidermal 
growth factor receptor. This categorization was a helpful 
way in order to predict the outcome and choose the best 
treatment option [5, 6]. Mutations in BRCA1 and BRCA2 
are some examples of genomic instabilities which are the 
most prominent cause of breast cancer [7–9]. Several 
studies indicated that a variety of techniques could be 
used in the treatment of different cancers such as breast 
cancer (i.e., cell-, gene-, and nanotechnology-based ther-
apies) [10–17]. Despite emerging new and effective ther-
apeutic platforms in the treatment of breast cancer, new 
approaches are needed [18, 19]. In this regard, it seems 
that more understanding of cellular and molecular path-
ways involved in breast cancer pathogenesis could con-
tribute to the development of new therapies [18].
In the past, scientists called 98% non-protein coding 
human genome as “junk” DNA. These DNAs produce 
RNAs which are not translated into proteins. This group 
is known as non-coding RNAs (non-encoding RNAs) 
which has two main subgroups: regulatory non-coding 
RNAs and housekeeping non-coding RNAs. The regula-
tory non-coding RNAs are also sorted into two subdivi-
sions by their length: short chain non-coding RNAs and 
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long chain non-coding RNAs. Short chain non-coding 
RNAs include small interfering RNAs (siRNAs), micro-
RNAs (miRNAs), and piwi-interacting RNAs (piRNAs) 
[20]. Moreover, long chain non-coding RNAs are known 
as long non-coding RNAs (lncRNAs) and circularRNAs 
[20, 21]. Recently, it has been revealed that non-coding 
RNAs have considerable roles in modifying epigenetics 
and regulating gene-level and chromosome-level expres-
sions in order to cell differentiation controlling [22–24]. 
piRNAs are RNA molecules with the estimated size of 
26–31 nt binding to Piwi proteins [25, 26]. The Piwi pro-
tein with the polycomb group proteins (PcGs) together 
bind to genomic PcG response elements in order to act 
as a regulatory factor. Therefore, piRNAs have a regula-
tory function in the body [27]. PiRNAs are classified 
into 3 group’s base on their origin: transposon-derived 
piRNA, lncRNA-derived piRNAs, and mRNA-derived 
piRNAs. Besides, there are two sub-clusters for piRNAs; 
one of them acts in premeiotic germ cells (pre-pachytene 
piRNAs) and another one function in meiosis and hap-
loid spermatid stage (pachytene piRNAs). The molecu-
lar features of both of these piRNAs are the same but 
pre-pachytene piRNAs cluster is totally different and 
has repetitive sequence elements [28]. piRNA-induced 
silencing complexes are produced by binding of piRNAs 
to PIWI proteins which generate a germline-specific 
member of the Argonaute family acting in silencing genes 
occurred by small RNAs [29].
piRNA-induced silencing complexes function by sup-
pressing transposons during transcription and post-
transcription leading to protection of the integrity of 
the germline genome. Moreover, regulation of cellular 
genes is another role of piRNAs in a variety of organ-
isms [30–32]. PIWI–piRNA pathway acts both in inside 
and outside the germline. Additionally, these RNAs can 
recognize “self” and “nonself” genes and regulate the 
latter [33]. PIWI protein genes also exist in Drosophila 
and mouse; (ago3, aubergine (aub), and piwi), (MIWI, 
MIWI2, and MILI) are their distinct genes respectively. 
It is observed in these eukaryotes that PIWI proteins are 
involved in transposon silencing, undeniable function 
in gonadal development, male and female fertility, DNA 
methylation and etc. [34]. In addition to gonadal func-
tions of PIWIs, they play roles in somatic tissues, espe-
cially stem cells. Up to now, four human PIWIs have been 
identified including HIWI (also known as PIWIL1), HILI 
(also known as PIWIL2), HIWI2 (also known as PIWIL4) 
and HIWI3 (also known as PIWIL3) [31]. Recent find-
ings investigated the role of piRNAs in several cancers 
including lung cancer [35], hepatocellular carcinoma 
[36], gastric cancer [37], multiple myeloma [38] and colo-
rectal cancer [39]. Hopefully, based on new research, 
piRNAs may be potential biomarkers which can be used 
as a tool to diagnose or treat breast cancer. Thus, this 
review aimed to discuss the role of piRNAs in breast can-
cer progression and metastasis as well as its molecular 
mechanisms.
PiRNA biosynthesis
While the transcription of transposon-derived piRNAs 
occurs from both genomic strands, sense and antisense 
piRNAs can be generated. While the origin of mRNA-
derived piRNAs is the 3′ untranslated regions of mRNAs, 
the lncRNAs-derived piRNAs originate from the entire 
lncRNA transcript [40]. Unlike miRNAs and siRNAs 
which are dependent on RNAse III Dicer for their mat-
uration, piRNA biogenesis is a Dicer-independent pro-
cess [41, 42]. Additional post-transcriptional processes 
are necessary for the full maturation of piRNAs precur-
sors. The primary synthesis and ‘ping-pong’ amplifica-
tion are the two mechanisms which are used after the 
transcription in order to produce mature piRNAs [43]. 
In the simplest scenario, in gonad somatic cells of Dros-
ophila, riboendonuclease Zucchini cleaves the primary 
transcript at first. After the incorporation of 3′ fragment 
in PIWI proteins, it is trimmed to its final length by a 
3′ to 5′ exonuclease. The enzyme Hen1 methylate the 2′ 
hydroxy group of the 3′ end. Meanwhile, 5′ end residue 
of incorporated piRNA in PIWI has a strong bias for 
the residues of uridine. Then, piRNAs bind PIWI pro-
teins and form piRNA/PIWI complexes [44]. Finally, 
these complexes migrate to the nucleus where they can 
Fig. 1 Factors related to PIWI proteins and piRNAs in breast cancer
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mobilize the silencer machinery and block their target 
gene transcription. Therefore, heterochromatin which 
is transcriptionally silent will be established through the 
piRNA-mediated recruitment of histone methyltrans-
ferases [45]. In the cytoplasm, the ping-pong mechanism 
amplifies the accumulation of piRNAs after the produc-
tion of primary piRNA [44]. Unlike the primary synthe-
sis which is related to PIWI proteins, in this process, 
piRNA/Ago3 or piRNA/Aub complexes are formed. An 
RNA sequence will be generated by the piRNA/Ago3 
complex which acts as a substrate used for producing 
new piRNA and the generated piRNA can load an Aub 
protein [46]. In fact, through an amplifying mechanism, 
the products of piRNAs result in the formation of sub-
strate for other functional piRNAs [47]. While studies 
indicated that ‘ping-pong’ mechanism exists in zebrafish, 
D. melanogaster and primitive animals, findings reveal 
that the biogenesis of piRNAs in mice is not dependent 
on the ‘ping-pong’ cycle [47, 48].
As a mechanism which is firstly explained in ovarian 
germline of fly, the endonucleolytic action of cytosolic 
PIWI leads to the formation of two cleavage fragments. 
Then, new mature piRNA is produced through the par-
ticipation of the downstream fragment in biogenesis 
pathway of piRNA. Noteworthy, PIWI slicing generates 
5′ end of secondary piRNAs [44, 49]. Moreover, it is 
reported that the downstream cleavage fragment can be 
the origin of an extensive biogenesis of piRNAs [50–52]. 
In inchworming process, the fragment produces other 
non-overlapping piRNAs in a direction occurring from 5′ 
to 3′ [51]. Inchworming-produced primary piRNAs load 
into PIWI proteins of fly nucleus. Two PIWI proteins of 
mouse have been showed to have a similar association. 
In diverse species, biogenesis of piRNA happens near 
the mitochondrial surface, and different mitochondrial 
membrane-anchored factors are involved [53]. In mice, 
two cytoplasmic PIWI proteins including MILI, and 
MIWI, receive processed pachytene piRNAs at intermi-
tochodrial cement (IMC) [53].In fact, what ensures that 
transposons remain silenced is the relation between cyto-
plasmic MILI and nuclear MIWI2 in the mouse embry-
onic male germline [54]. Moreover, the slicer activity of 
MILI has been reported to be essential in the produc-
tion of MIWI2-associated piRNAs [55]. In a study of 
Yang et  al. [56], it is shown that transcript endonucleo-
lytic slicing which is done by cytosolic PIWI proteins of 
mouse, MILI, stimulates its 5′ → 3′ processing. This event 
eventually leads to the production of non-overlapping 
fragments which are new piRNAs. Then, new piRNAs 
accumulate in nuclear MIWI2 and cytosolic MILI. Exo-
nuclease domain-containing 1 (EXD1) is found to be the 
partner of TDRD12 which is a factor for the biogenesis 
of MIWI2 piRNA. Despite the inactivity of EXD1 as a 
nuclease, this factor plays its role in PET (PIWI-EXD1-
Tdrd12) complex as an adaptor of RNA. Altogether, this 
study concluded that PIWI stimulates the piRNA biogen-
esis and EXD1 enhances the production of piRNAs and 
ensures the effective entry of small RNAs to the PIWI 
proteins of nucleus [56].
PiRNAs and cancer: molecular mechanisms
In addition to PIWI proteins, piRNAs have significant 
roles in the carcinogenesis. Reproductive tissues express 
a great number of piRNAs. PiRNAs are also expressed 
in brain tissue as well as exosomes which are derived 
from the human plasma [57, 58]. While miRNAs serve as 
the regulator of post-transcriptional activities, piRNAs 
are considered to act as the epigenetic regulator which 
is involved in angiogenesis, invasiveness, growth and 
metastasis of tumors [59, 60]. Up to now, several studies 
concerned with the role of piRNAs in different processes 
which are involved in cancer.
PiR-651 has been shown to play a role in carcinogenesis 
through affecting apoptosis, proliferation, and migration. 
This piRNA is concluded to be overexpressed in several 
cancer cell lines such as lung, colon, gastric, breast can-
cer, hepatic carcinoma and mesothelioma. Moreover, it 
is found that the inhibitor of piR-651 can make cancer 
cells stop in G2/M phase. Indeed, due to the impacts of 
the piRNA pathway on the balance of cell division and 
self-renewal, any interruption in this pathway may make 
an effect on the progression of cancer. There are sev-
eral studies indicating that the expression of piRNAs is 
decreased in multiple cancers resulting in the prolifera-
tion of cancer cells and progression of tumors [61]. As 
the piR-55490 is downregulated in lung cancer, research 
indicates that the proliferation of lung cancer cells can be 
reduced through the recovery of this piRNA [62]. Simi-
lar to what miRNAs do, piR-55490 decreases the decay of 
mTOR mRNA through binding to its 3′ UTR; thus, inhib-
iting Akt/mTOR signaling in lung cancer cells. In other 
words, piRNA targets oncogenic mRNA and leads to the 
suppression of tumor cells [62].
Novel research which is concerned with somatic roles 
of piRNAs has revealed that piRNAs may be involved 
in the regulation of gene expression by histone modifi-
cation and DNA methylation [31, 63–65]. Meanwhile, 
DNA hypomethylation, histones hypoacetylation and 
gene-specific DNA hypermethylation are general epi-
genetic changes occurred in cancer leading to R-ras 
and cyclin D2 oncogenes activation as well as silencing 
RB1 and p16 tumor suppressor genes [59, 66]. PIWIL4 
(MIWI2) embedded in the nucleus leads to the meth-
ylation of retrotransposons promoter sequences and 
suppress them through methylation of de novo DNA 
in male mice before birth. Furthermore, by mutating 
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MIWI2 and MIWI, retrotransposon promoters meth-
ylation will be lost in the mouse testes [67, 68]. In sev-
eral types of cancer such as lung, breast, colorectal, 
and stomach cancer, piR-1245 is reported to be over-
expressed and considered to be involved in the carcino-
genesis [69]. In colorectal cancer, this piRNA has been 
observed to regulate the progression of the tumor by 
targeting ATF3, BTG1, DUSP1, FAS, NFKBIA, UPP1, 
SESN2, TP53INP1 and MDX1 and associated with poor 
differentiation and metastasis [70]. While DNMT3L/
PIWIL2/TDRD1 complex can cause DNA methylation 
loss at transposons (LINE1 and IA), data has shown that 
in primary tumors of the testicle, transcriptional silenc-
ing is linked to the methylation of 5′ end promoter CpG 
in different genes including PIWIL1, PIWIL2, PIWIL4 
and TDRD1 [71].
There is a theory explaining that piRNAs and PIWI 
proteins may lead to a characteristic found in can-
cers, aberrantly “stem-like” state. This stem-like state is 
occurred by the of PIWI-piRNA complexes that lead to 
genomic silencing following the aberrant methylation of 
DNA. Moreover, cancer cells which are similar to stem 
cells have shown to gain metastatic features as well as 
undergoing epithelial-mesenchymal transition. Despite 
the fact that epigenetic aberrancies are important tumor 
tissues properties, they are not well-understood yet. 
Emerging evidence collected from different types of 
tumors has suggested that cancers reflect the epigenetic 
state of adult progenitor cells [72]. Moreover, inhibiting 
mechanisms affecting the hypermethylation of DNA is 
similar to progenitor cells [73]. However, in progenitor 
cells, DNA methylation is responsible for silencing the 
differentiation genes, promoter site of tumor suppres-
sor genes are the regions where the hypo-methylation 
occurred in cancer [73]. In stem cells, differentiation 
genes are silenced by EZH2 methyltransferase which 
mediates repressive histone 3 lysine 27 tri-methylation 
mark [74]. Furthermore, overexpression of EZH2 is 
observed in many cancers such as breast and prostate 
cancer which are associated with tumor aggressiveness 
[75]. These findings together may confirm that cancers 
have an aberrantly “stem-like” epigenetic state [76]. Find-
ings have shown that piRNAs are considered to take part 
in different mechanisms involved in cancer including 
tumor cells proliferation, apoptosis, cancer spreading, 
and invasion and possibly be a potential biomarker for 
prognosis and diagnosis of cancer. The apoptosis-induc-
ing role of piRNAs and their ability to prevent cell prolif-
eration has been investigated in various tumors such as 
breast cancer, bladder cancer, multiple myeloma, gastric 
cancer, glioma and etc. The inhibitory function of piRNA 
on metastasis and invasion has been also shown in breast 
cancer, clear cell renal cell carcinoma, gastric cancer, and 
hepatocellular carcinoma [77].
PiRNAs and breast cancer
For the first time, Fu et  al. [78] found that epigenetic 
functions occurring by piRNAs are able to make an 
effect on cancer-related pathways which are also involved 
in human breast cancer. Although their findings were 
restricted to one cell line, it is suggested to be capable 
to affect various genes methylation in MCF7. Indeed, 
the results showed that certain piRNAs, like miRNAs 
associated with cancer, probably target multiple genes 
thus any irruption in their function may lead to serious 
consequences such as several downstream of cancer-
related mechanisms. Based on evidence gathered from 
this study, piR-021285 can modulate the invasiveness of 
human breast cancer through methylation of the pro-
invasive ARHGAP11A gene at CpG site which is existed 
in the region of 5′ UTR/first exon. Consequentially, the 
expression of pro-apoptotic mRNA will be decreased and 
apoptosis will be inhibited.
In a recent study, it is observed that piRNA-36,712 
level in breast tumor tissues was significantly lower than 
in healthy tissues. In addition, low levels of this piRNA 
were related to poor outcome in breast cancer patients. 
Several studies showed that a retroprocessed pseudo-
gene of  SEPW1 “SEPW1P” produces RNAs which have 
interaction with piRNA-36,712. Thus, the competition 
of  SEPW1  mRNA with  SEPW1P  RNA for microRNA-7 
and microRNA-324 leads to SEPW1 suppression. More-
over, downregulation of piRNA-36,712 resulting in an 
increase in SEPW1 expression may inhibit P53 which 
contributes to Slug upregulation and P21 and E-cadherin 
levels reduction. Altogether, these alterations cause to 
promote the proliferation of cancer cells, invasion and 
migration. Besides, piRNA-36,712 can amplify the effects 
of chemotherapeutic agents, paclitaxel and doxorubicin 
in breast cancer. These findings implicate that piRNA-
36,712 is a new tumor suppressor which can be used 
in order to provide a prognosis and treat breast cancer 
patient [79].
In another study, the role of piRNAs in human breast 
cancer cells was examined. Using statistical analysis (Wil-
coxon Mann–Whitney test) revealed a tumor-specific 
pattern containing 8 piRNAs which are expressed differ-
entially. Five of these piRNA expression levels were lower 
in breast cancer tissues including DQ596670, DQ598183, 
DQ597341, DQ598252 and DQ596311 and three of them 
had higher expression levels in comparison with normal 
tissues, including DQ598677,  DQ597960  and  DQ57099
4. Recent research implicated that piRNAs have a role 
similar to miRNAs as they enhance to the formation of 
specific RNA silencing complexes (pi-RISC) promoting 
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suppression of RNAs through an incomplete base-pair-
ing between two of them [80, 81]. In Rizzo et  al. [82] 
study applying stringent thermodynamic parameters 
and binding energy thresholds, it is indicated that each 
piRNA differentially expressed in cancer tissues was 
complementary to 23 to 383 RNAs comprising: mRNAs, 
pseudogene transcripts and long ncRNAs. These mRNAs 
probably targeted by piRNAs encode proteins which 
mainly have functions in breast cancer important cellular 
processes including cell-to-cell signaling and interaction, 
cell death and survival, cell cycle, and DNA replication 
and repair. Hu et  al. [83] evaluated piRNA expression 
in tumor tissues and their non-tumoral counterparts by 
real-time PCR. The results indicated that four out of six 
piRNAs were up-regulated in breast cancer tissue includ-
ing piR-4987, piR-20365, piR-20485, and piR-20582. Also, 
upregulation of piR-4987 expression was linked with 
lymph node positivity resulting in poorer outcome in 
breast cancer patients.
The most prominent prognostic indicator in breast 
cancer is axillary lymph node status which is also 
used to indicate the capability of the tumor to metas-
tasis [84]. Based on this information, piR-4987 is a key 
player in progression, invasion and tumor spreading, 
thus piR-4987 overexpression leads to more aggres-
sive breast cancer. Due to piRNAs role which is silenc-
ing transposons leading to genetic mutation and 
being associated with cancer, piRNAs may affect can-
cer by regulation of transposons. In addition, piRNAs 
probably have a regulatory effect on genes responsible 
for coding proteins. Thus, piRNA in cancer can regulate 
both oncogenes and anti-oncogenes. Another investi-
gation on piR-651 revealed that its upregulation occurs 
in multiple cancers including breast cancer. This find-
ing suggested that piR-651 may be an oncogene which 
was confirmed in gastric cancer. Guo et  al. [39] used 
piR-651 inhibitor which leads to suppressing of gas-
tric cancer cell growth. Their study implied that any 
disruption in the balance of this piRNA may result in 
a significant effect on tumor progression. The piR-932 
expression has been also investigated in breast cancer. 
It is declared that piR-932 is significantly expressed 
higher in breast tumor tissues than in normal tissues. 
Furthermore, it can create immune complexes by 
immunoprecipitation with the help of PIWIL2. Also, in 
PIWIL2 + breast cancer stem cells, due to the methyla-
tion of Latexin promotor region (CpG island), Latexin 
expression levels are significantly lower than normal. 
These findings introduce a potential target which is the 
combination of piR-932 and PIWIL2. This complex, as 
a positive regulator promotes Latexin methylation and 
can be used in order to block the metastasis in breast 
cancer [85].
PIWI proteins and breast cancer
Similarly, PIWI proteins also have significant roles in dif-
ferent cancers such as breast cancer. In spite of extensive 
research about cancer, only recent articles have discussed 
PIWI proteins roles in this area [86]. PIWIL4 Gene is 
Table 1 Experimental studies that investigated the role of piRNAs in breast cancer
PiRNA Function Type of breast cancer or its cell line Model Expression References
PiR-36712 Promotes cancer cell proliferation, invasion 
and migration
Invasive breast ductal carcinoma In vitro and In vivo Underexpressed [79]
PiR-34736 Progression of cell cycle Invasive breast ductal carcinoma In vitro Underexpressed [82]
PiR-36249 Progression of cell cycle Invasive breast ductal carcinoma In vitro Underexpressed [82]
PiR-35407 Progression of cell cycle Invasive breast ductal carcinoma In vitro Underexpressed [82]
PiR-34377 Progression of cell cycle Invasive breast ductal carcinoma In vitro Underexpressed [82]
PiR-36318 Progression of cell cycle Invasive breast ductal carcinoma In vitro Underexpressed [82]
PiR-36026 Progression of cell cycle Invasive breast ductal carcinoma In vitro Overexpressed [82]
PiR-31106 Progression of cell cycle Invasive breast ductal carcinoma In vitro Overexpressed [82]
PiR-36743 Progression of cell cycle Invasive breast ductal carcinoma In vitro Overexpressed [82]
PiR-20582 Tumor marker Invasive breast ductal carcinoma In vitro Overexpressed [83]
PiR-4987 Lymph node positivity Invasive breast ductal carcinoma In vitro Overexpressed [83]
PiR-20365 Tumor marker Invasive breast ductal carcinoma In vitro Overexpressed [83]
PiR-20485 Tumor marker Invasive breast ductal carcinoma In vitro Overexpressed [83]
PiR-651 Tumor progression Bcap-37 cell line In vitro Overexpressed [39]
PiR-021285 Modulates
Breast cancer invasiveness
MCF7 breast cancer cell lines In vitro Overexpressed [78]
PiR-932 Promotes methylation of Latexin and form 
immune complexes
Breast cancer stem cells(CSC) In vitro Overexpressed [85]
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one of the upregulated genes in breast cancer which 
is highly expressed not only in breast cell lines but also 
in breast cancer samples. Findings have shown that in 
various cancers, PIWI proteins are expressed aberrantly. 
For instance, the overexpression of PIWIL2 has been 
observed in breast cancer [76, 87–92].
Moreover, Wang et al. [86] investigated the three active 
PIWI genes (PIWIL1, PIWIL2 and PIWIL4) expression. 
However, this study performed on six different types 
of breast cancer cell lines and the results showed that 
PIWIL1 expression level is significantly higher in four 
cancer cell line than in normal breast cell line. Addi-
tionally, PIWIL2 over-expressed in two cancer cell lines. 
Furthermore, PIWIL4 has remarkably higher expression 
levels in five cell lines. Another study also found that 
in 334 out of 1086 breast cases, PIWIL2 increased in 
breast cancer stem cells. Significantly, PIWIL2 has been 
linked to age, size of the tumor, histological type, tumor 
stage and lymph node metastasis. As mentioned earlier, 
PIWIL2 and piR-932 together can create immune com-
plexes [85].
Conclusions
PiRNAs as a member of non-coding RNAs family have 
various roles in the germline as well as in somatic cells. 
It is found that piRNAs act as regulators in many cancers 
including breast cancer. Several studies have shown that 
piRNAs are involved in tumor cell’s proliferation, apop-
tosis, invasion and metastasis. Although the research 
in this area is in its infancy, several papers implied that 
piRNAs can be used as biomarkers to early diagnosis of 
the breast cancer and may be used as a treatment option 
for this cancer  (Fig.1 and Table  1). Expression patterns 
of piRNAs are different in breast cancer cell lines; in 
some of them, piRNAs expressions aberrantly increase 
but, in the others, piRNAs have been seen to be down-
regulated or they may be absent totally. Altogether, with 
further investigations, piRNAs may have a major role in 
the advancement of breast cancer research while there is 
a necessity to think beyond the usual breast cancer treat-
ments. Thus, piRNAs may be beneficial targets for diag-
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